Featured Research

from universities, journals, and other organizations

Tuberculosis Not The Only Risk From New Immunological Drugs

Date:
May 23, 2008
Source:
Infectious Diseases Society of America
Summary:
A new survey cautions physicians that drugs commonly prescribed for patients suffering from immunological disorders such as rheumatoid arthritis and inflammatory bowel disease may carry risks of serious infections other than the known risk of tuberculosis.

A new survey cautions physicians that drugs commonly prescribed for patients suffering from immunological disorders such as rheumatoid arthritis and inflammatory bowel disease may carry risks of serious infections other than the known risk of tuberculosis.

As many as 50 million Americans may suffer from immunological disorders that are treated with drugs that suppress immunity. Among these drugs are agents that inhibit tumor necrosis factor-α (TNF), a cytokine receptor involved in cellular communication. It is known that anti-TNF therapies are associated with an increased risk of tuberculosis.

The new survey of infectious diseases physicians indicates that there is probably greater risk for other serious infections in these patients. Survey respondents reported 73 cases of Staphylococcus aureus, 56 cases of histoplasmosis, and 32 nontuberculosis mycobacterial infections among patients using these immune-modulating therapies, compared to 17 tuberculosis cases.

Kevin Winthrop, MD, of the Oregon Health and Sciences University, said: "While much attention has so far focused on tuberculosis cases occurring in patients using anti-TNF therapies, our findings suggest that nontuberculosus mycobacterial infections, histoplasmosis, and invasive S. aureus infections might all be occurring more frequently than TB in this setting within the United States."

Patients are usually screened for tuberculosis prior to initiating anti-TNF therapy and this should continue, say the authors. However, clinicians should be vigilant not just for TB, but also for nontuberculosis mycobacterial infections in patients who are beginning or using these drugs, particularly those patients with underlying lung disease from rheumatoid arthritis, emphysema, or other conditions. In addition, clinicians should also be vigilant for mycobacterial infections in patients using rituximab (Rituxan), as a small number of the cases reported in this series occurred in patients using this B lymphocyte depletion therapy.

 The survey published is in the June 1 issue of Clinical Infectious Diseases, currently available online.

The survey was conducted via the Emerging Infections Network of the Infectious Diseases Society of America. The network comprises about 900 infectious diseases physicians, who communicate via fax or the Internet. In this survey, 426 network members from throughout North America reported on the tuberculosis or nontuberculosis mycobacterial infections that they had seen in the previous six months. This survey and its results highlight the utility of the network as an active surveillance tool for emerging infectious complications associated with new drug therapies.


Story Source:

The above story is based on materials provided by Infectious Diseases Society of America. Note: Materials may be edited for content and length.


Cite This Page:

Infectious Diseases Society of America. "Tuberculosis Not The Only Risk From New Immunological Drugs." ScienceDaily. ScienceDaily, 23 May 2008. <www.sciencedaily.com/releases/2008/05/080520110412.htm>.
Infectious Diseases Society of America. (2008, May 23). Tuberculosis Not The Only Risk From New Immunological Drugs. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2008/05/080520110412.htm
Infectious Diseases Society of America. "Tuberculosis Not The Only Risk From New Immunological Drugs." ScienceDaily. www.sciencedaily.com/releases/2008/05/080520110412.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) — Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) — Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) — President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins